Health Care & Life Sciences » Biotechnology | Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc. | Ownership

Companies that own Conatus Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Vanguard Group, Inc.
1,353,087
4.5%
10,369
0%
06/30/2018
BlackRock Fund Advisors
891,607
2.97%
-863,706
0%
06/30/2018
AXA Investment Managers UK Ltd.
443,624
1.48%
5,645
0.01%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
407,896
1.36%
320,376
0%
06/30/2018
Millennium Management LLC
369,124
1.23%
11,445
0%
06/30/2018
United Capital Financial Advisers LLC
327,076
1.09%
-499
0.01%
06/30/2018
Alambic Investment Management LP
264,665
0.88%
178,461
0.4%
06/30/2018
Crestline Management LP
252,723
0.84%
252,723
0.13%
06/30/2018
BlackRock Advisors LLC
244,651
0.81%
40,964
0%
06/30/2018
Acadian Asset Management LLC
243,759
0.81%
-337,213
0%
06/30/2018

About Conatus Pharmaceuticals

View Profile
Address
16745 West Bernardo Drive
San Diego California 92127
United States
Employees -
Website http://www.conatuspharma.com
Updated 07/08/2019
Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.